Changsong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Changsong Wang has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Yu Xin
Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China
7 shared publicationsLifeng Shen
Department of Critical Care Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, China
6 shared publicationsYanqi Liu
Department of Critical Care Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, China
6 shared publications- Kaijiang Yu
Department of Critical Care Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, China
5 shared publications Yu Xiao
Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University
5 shared publicationsMengyao Yuan
Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China
4 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Xia & He Publishing in Journal of Translational Critical Care Medicine
- Vol. 8 (3)
Evaluation of Human Serum Albumin in Neurocritical Care: A Narrative Review of Current Applications and Treatment Challenges
Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management of critically ill patients, including those with acute brain injury. HSA is thought to exert neuroprotective effects through four complementary mechanisms: oncotic/volume expansion and hemodilution, antioxidant and anti-inflammatory effects, HSA-nitric oxide-mediated antithrombotic activity, and glycocalyx stabilization, although the precise pathways remain incompletely understood. Despite its biological rationale, the clinical efficacy of HSA in severe neurological disorders remains inconclusive, and few guidelines provide specific recommendations for its use in neurological care. This uncertainty stems primarily from the complex etiology and heterogeneous pathophysiology of neurological disorders, as well as inconsistent findings across existing studies. This narrative review aims to summarize the current evidence on HSA use in traumatic brain injury, acute ischemic stroke, and aneurysmal subarachnoid hemorrhage, identify existing knowledge gaps, and provide insights for future research and clinical practice. We screened records from PubMed, Embase, the Cochrane Library, CNKI, and Yiigle, as well as ClinicalTrials.gov, ChiCTR, and ChinaDrugTrials. A total of 29 human and animal studies were included. Collectively, available evidence supports a biological rationale for HSA therapy in neurocritical care, yet its clinical benefit remains incompletely established and substantial challenges persist. Prospective randomized controlled trials are warranted to clarify the efficacy and safety of HSA and determine whether preliminary encouraging findings can inform standardized guidelines and expert consensus recommendations, particularly regarding optimal concentration, timing, and patient selection.
- 28 September 2026
- Published by Xia & He Publishing in Journal of Translational Critical Care Medicine
- Vol. 8 (3)
Open AccessEvaluation of Human Serum Albumin in Neurocritical Care: A Narrative Review of Current Applications and Treatment Challenges
Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management of critically ill patients, including those with acute brain injury. HSA is thought to exert neuroprotective effects through four complementary mechanisms: oncotic/volume expansion and hemodilution, antioxidant and anti-inflammatory effects, HSA-nitric oxide-mediated antithrombotic activity, and glycocalyx stabilization, although the precise pathways remain incompletely understood. Despite its biological rationale, the clinical efficacy of HSA in severe neurological disorders remains inconclusive, and few guidelines provide specific recommendations for its use in neurological care. This uncertainty stems primarily from the complex etiology and heterogeneous pathophysiology of neurological disorders, as well as inconsistent findings across existing studies. This narrative review aims to summarize the current evidence on HSA use in traumatic brain injury, acute ischemic stroke, and aneurysmal subarachnoid hemorrhage, identify existing knowledge gaps, and provide insights for future research and clinical practice. We screened records from PubMed, Embase, the Cochrane Library, CNKI, and Yiigle, as well as ClinicalTrials.gov, ChiCTR, and ChinaDrugTrials. A total of 29 human and animal studies were included. Collectively, available evidence supports a biological rationale for HSA therapy in neurocritical care, yet its clinical benefit remains incompletely established and substantial challenges persist. Prospective randomized controlled trials are warranted to clarify the efficacy and safety of HSA and determine whether preliminary encouraging findings can inform standardized guidelines and expert consensus recommendations, particularly regarding optimal concentration, timing, and patient selection.
- Open Access
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1848531
Investigation of pathogen resistance in Chinese cancer patients based on bacterial resistance surveillance in 23 provinces, 2016–2023
Background: Infection is a common and often fatal complication in cancer patients. Notably, cancer patients account for up to 21% of all sepsis cases. Furthermore, sepsis is present in 30% of all deaths among those hospitalized with cancer. However, comprehensive antimicrobial resistance (AMR) surveillance data specific to this population are lacking. This gap hinders the effectiveness of antimicrobial stewardship programs (ASPs). Methods: We investigated bacterial distribution and AMR patterns in Chinese cancer patients to inform empirical therapy and ASPs. This multicenter retrospective study collected hospital-wide clinical isolates and drug-susceptibility data from 23 cancer centers during 2016–2023. All procedures followed standardized methods in accordance with national surveillance protocols and Clinical and Laboratory Standards Institute guidelines. Data were subjected to dual validation using WHONET and a domestically developed big-data system. Results: Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers. Predominant Gram-negative species were Klebsiella pneumoniae , Escherichia coli , Pseudomonas aeruginosa , Acinetobacter baumannii , and Enterobacter cloacae . Escherichia coli exhibited low imipenem resistance (0.9–1.5%) with a recent increase (2021–2023: APC = 16.57%, p < 0.001). Klebsiella pneumoniae showed stable imipenem resistance (1.6–1.9%) but increasing meropenem resistance (0.4–1.6%). Pseudomonas aeruginosa imipenem resistance declined (12.5–7.9%), while meropenem resistance remained stable (7.0–5.2%); while Acinetobacter baumannii carbapenem resistance increased substantially (imipenem: 9.6–18.4%; meropenem: 4.7–18.8%). Leading Gram-positive organisms were Staphylococcus epidermidis , Staphylococcus aureus , Enterococcus faecium , Enterococcus faecalis , and Staphylococcus haemolyticus . Methicillin-resistant Staphylococcus aureus (MRSA) resistance declined over five years, with no resistance to linezolid, vancomycin, or teicoplanin. Enterococcus spp. gradually developed resistance to last-resort antibiotics. Conclusion: Carbapenem resistance among common Gram-negatives in cancer patients was below national averages. MRSA and enterococcal resistance were also below national levels. These findings underscore the unique resistance epidemiology in oncology, supporting tailored guidelines and dedicated surveillance.
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1848531
Open AccessInvestigation of pathogen resistance in Chinese cancer patients based on bacterial resistance surveillance in 23 provinces, 2016–2023
Background: Infection is a common and often fatal complication in cancer patients. Notably, cancer patients account for up to 21% of all sepsis cases. Furthermore, sepsis is present in 30% of all deaths among those hospitalized with cancer. However, comprehensive antimicrobial resistance (AMR) surveillance data specific to this population are lacking. This gap hinders the effectiveness of antimicrobial stewardship programs (ASPs). Methods: We investigated bacterial distribution and AMR patterns in Chinese cancer patients to inform empirical therapy and ASPs. This multicenter retrospective study collected hospital-wide clinical isolates and drug-susceptibility data from 23 cancer centers during 2016–2023. All procedures followed standardized methods in accordance with national surveillance protocols and Clinical and Laboratory Standards Institute guidelines. Data were subjected to dual validation using WHONET and a domestically developed big-data system. Results: Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers. Predominant Gram-negative species were Klebsiella pneumoniae , Escherichia coli , Pseudomonas aeruginosa , Acinetobacter baumannii , and Enterobacter cloacae . Escherichia coli exhibited low imipenem resistance (0.9–1.5%) with a recent increase (2021–2023: APC = 16.57%, p < 0.001). Klebsiella pneumoniae showed stable imipenem resistance (1.6–1.9%) but increasing meropenem resistance (0.4–1.6%). Pseudomonas aeruginosa imipenem resistance declined (12.5–7.9%), while meropenem resistance remained stable (7.0–5.2%); while Acinetobacter baumannii carbapenem resistance increased substantially (imipenem: 9.6–18.4%; meropenem: 4.7–18.8%). Leading Gram-positive organisms were Staphylococcus epidermidis , Staphylococcus aureus , Enterococcus faecium , Enterococcus faecalis , and Staphylococcus haemolyticus . Methicillin-resistant Staphylococcus aureus (MRSA) resistance declined over five years, with no resistance to linezolid, vancomycin, or teicoplanin. Enterococcus spp. gradually developed resistance to last-resort antibiotics. Conclusion: Carbapenem resistance among common Gram-negatives in cancer patients was below national averages. MRSA and enterococcal resistance were also below national levels. These findings underscore the unique resistance epidemiology in oncology, supporting tailored guidelines and dedicated surveillance.
- Open Access
- 1 July 2026
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 14 (1) , 86
Timing-dependent renal protection of dapagliflozin in endotoxemic diabetic mice by real-time GFR and biomarkers
Introduction: Type 2 diabetes mellitus (T2DM) increases susceptibility to sepsis-associated acute kidney injury (SA-AKI). While guidelines support chronic sodium-glucose cotransporter 2 (SGLT2) inhibitor use in T2DM, their efficacy and optimal intervention timing in acute sepsis remain unclear. We hypothesized that this efficacy is timing-dependent. To test this, we utilized a T2DM mouse model subjected to graded lipopolysaccharide (LPS) challenges as a clinically relevant surrogate for sepsis. Notably, to precisely capture the longitudinal and dynamic trajectory of renal function, we incorporated continuous real-time transcutaneous glomerular filtration rate (tGFR) monitoring. We evaluated the SGLT2 inhibitor dapagliflozin (DAPA) across three regimens representing distinct clinical scenarios: preventive (pre-LPS only, modeling prior chronic use), therapeutic (initiated post-LPS, modeling de novo intensive care initiation), and whole-course (continuous administration, modeling treatment continuation). Results: Following LPS challenge, T2DM exacerbated renal dysfunction across all doses and impaired endogenous functional recovery. High-resolution real-time tGFR tracking and subsequent biomarker analyses revealed that the renoprotective effect of DAPA was dependent on the timing of intervention. In moderate endotoxemia, both therapeutic and whole-course regimens were superior to the preventive regimen. Compared to preventive administration alone, initiating or continuing treatment during the acute insult (therapeutic and whole-course regimens) more effectively preserved early glomerular filtration rate (GFR) trajectories, attenuated the rise in tubular injury markers, and promoted histological repair. Conclusions: Supported by dynamic renal function monitoring, this study demonstrates that DAPA provides significant renoprotection in a preclinical T2DM model of endotoxemia-associated acute kidney injury. This efficacy is closely associated with the timing of intervention, with greater protective effects observed when treatment is initiated during or maintained after the acute endotoxemic challenge. These preclinical findings suggest that intervention timing could be a key determinant of SGLT2 inhibitor efficacy, providing a scientific rationale for evaluating the prompt initiation or continuation of this therapy in diabetic patients presenting with acute sepsis.
- 1 July 2026
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 14 (1) , 86
Open AccessTiming-dependent renal protection of dapagliflozin in endotoxemic diabetic mice by real-time GFR and biomarkers
Introduction: Type 2 diabetes mellitus (T2DM) increases susceptibility to sepsis-associated acute kidney injury (SA-AKI). While guidelines support chronic sodium-glucose cotransporter 2 (SGLT2) inhibitor use in T2DM, their efficacy and optimal intervention timing in acute sepsis remain unclear. We hypothesized that this efficacy is timing-dependent. To test this, we utilized a T2DM mouse model subjected to graded lipopolysaccharide (LPS) challenges as a clinically relevant surrogate for sepsis. Notably, to precisely capture the longitudinal and dynamic trajectory of renal function, we incorporated continuous real-time transcutaneous glomerular filtration rate (tGFR) monitoring. We evaluated the SGLT2 inhibitor dapagliflozin (DAPA) across three regimens representing distinct clinical scenarios: preventive (pre-LPS only, modeling prior chronic use), therapeutic (initiated post-LPS, modeling de novo intensive care initiation), and whole-course (continuous administration, modeling treatment continuation). Results: Following LPS challenge, T2DM exacerbated renal dysfunction across all doses and impaired endogenous functional recovery. High-resolution real-time tGFR tracking and subsequent biomarker analyses revealed that the renoprotective effect of DAPA was dependent on the timing of intervention. In moderate endotoxemia, both therapeutic and whole-course regimens were superior to the preventive regimen. Compared to preventive administration alone, initiating or continuing treatment during the acute insult (therapeutic and whole-course regimens) more effectively preserved early glomerular filtration rate (GFR) trajectories, attenuated the rise in tubular injury markers, and promoted histological repair. Conclusions: Supported by dynamic renal function monitoring, this study demonstrates that DAPA provides significant renoprotection in a preclinical T2DM model of endotoxemia-associated acute kidney injury. This efficacy is closely associated with the timing of intervention, with greater protective effects observed when treatment is initiated during or maintained after the acute endotoxemic challenge. These preclinical findings suggest that intervention timing could be a key determinant of SGLT2 inhibitor efficacy, providing a scientific rationale for evaluating the prompt initiation or continuation of this therapy in diabetic patients presenting with acute sepsis.
- Open Access
- 12 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1449-1462
Integrated Study of Vancomycin-Induced Nephrotoxicity in the Context of Sepsis
Background: Vancomycin (VAN) is widely used in sepsis but may exacerbate sepsis-associated acute kidney injury (SA-AKI). The mechanisms by which VAN aggravates renal injury in the septic context remain unclear, and early functional changes are difficult to detect using conventional biomarkers. Methods: C57BL/6 mice were subjected to lipopolysaccharide (LPS)-induced sepsis, VAN-induced nephrotoxicity, or combined injury. Renal function was continuously assessed using non-invasive percutaneous real-time glomerular filtration rate (GFR) monitoring. Conventional renal injury markers, histopathology, and transcriptomic analyses were performed at 2, 24, and 72 hours. Results: In septic mice, VAN administration caused an early and marked decline in GFR, preceding increases in serum creatinine and blood urea nitrogen. Compared with sepsis alone, combined LPS and VAN treatment resulted in more sustained renal dysfunction and more severe tubular injury. Transcriptomic profiling identified early and persistent upregulation of Tnfrsf1a and sustained upregulation of Ccl20 in the combined injury model. Functional enrichment analyses revealed activation of inflammatory and immune-related pathways, including TNF signaling, cytokine–cytokine receptor interaction, and IgSF cell adhesion molecule signaling. Conclusions: Real-time GFR monitoring demonstrates that vancomycin exacerbates SA-AKI by inducing early functional impairment. Transcriptomic changes suggest that enhanced inflammatory signaling and immune cell recruitment contribute to VAN-aggravated renal injury in sepsis.
- 12 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1449-1462
Open AccessIntegrated Study of Vancomycin-Induced Nephrotoxicity in the Context of Sepsis
Background: Vancomycin (VAN) is widely used in sepsis but may exacerbate sepsis-associated acute kidney injury (SA-AKI). The mechanisms by which VAN aggravates renal injury in the septic context remain unclear, and early functional changes are difficult to detect using conventional biomarkers. Methods: C57BL/6 mice were subjected to lipopolysaccharide (LPS)-induced sepsis, VAN-induced nephrotoxicity, or combined injury. Renal function was continuously assessed using non-invasive percutaneous real-time glomerular filtration rate (GFR) monitoring. Conventional renal injury markers, histopathology, and transcriptomic analyses were performed at 2, 24, and 72 hours. Results: In septic mice, VAN administration caused an early and marked decline in GFR, preceding increases in serum creatinine and blood urea nitrogen. Compared with sepsis alone, combined LPS and VAN treatment resulted in more sustained renal dysfunction and more severe tubular injury. Transcriptomic profiling identified early and persistent upregulation of Tnfrsf1a and sustained upregulation of Ccl20 in the combined injury model. Functional enrichment analyses revealed activation of inflammatory and immune-related pathways, including TNF signaling, cytokine–cytokine receptor interaction, and IgSF cell adhesion molecule signaling. Conclusions: Real-time GFR monitoring demonstrates that vancomycin exacerbates SA-AKI by inducing early functional impairment. Transcriptomic changes suggest that enhanced inflammatory signaling and immune cell recruitment contribute to VAN-aggravated renal injury in sepsis.
- Open Access
- 24 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Clinical characteristics and therapies of multi-organ immune related adverse events
Immune checkpoint inhibitors (ICIs) activate the immune system by blocking PD-1, CTLA-4, and PD-L1, thereby inducing autoimmune-mediated adverse reactions known as immune-related adverse events (irAEs). When two or more organs are involved, this condition is defined as multi-organ immune-related adverse events (multi-organ irAEs). Patients with multi-organ irAEs account for approximately 20%–30% of all irAE cases; however, clinical research focusing on this subset remains limited. The purpose of this study is to analyze the clinical characteristics, optimal therapeutic approaches, and mortality-related risk factors of multi-organ irAEs. We searched all case reports of irAEs associated with ICIs in the PubMed, Web of Science, Cochrane Library, and Embase databases from their inception to January 2022. Search terms included “Immune Checkpoint Inhibitors”, “Checkpoint Inhibitors, Immune”, “Immune Checkpoint Blockers”, “PD-L1”, “CTLA-4 Inhibitor”, “PD-1”, and “Case report”. After removing duplicate literature and applying strict inclusion/exclusion criteria, a total of 2,740 articles were included, encompassing 2,964 patients (782 with multi-organ irAEs and 2,182 with single-organ irAEs). Patients were stratified by the number of affected organs to compare clinical characteristics between multi-organ and single-organ irAE groups. For patients with multi-organ irAEs, subgroup analyzes were performed based on glucocorticoid dosage to identify optimal treatment strategies, and further stratified by survival status to explore potential mortality risk factors. No statistically significant differences in age or sex were observed between patients with multi-organ irAEs and those with single-organ irAEs (P > 0.05). However, the multi-organ irAE group exhibited significantly higher proportions of cardiovascular toxicity, thyroid toxicity, skin toxicity, and severe adverse reactions (P < 0.05), as well as a significantly elevated mortality rate (P < 0.05). Among patients with severe multi-organ irAEs, there were no significant differences in sex or age between high-dose and low-dose glucocorticoid subgroups (P > 0.05); notably, the high-dose glucocorticoid group had a significantly higher mortality rate (P < 0.05). For patients with non-severe multi-organ irAEs, no statistically significant differences in sex, age, mortality, or prognosis were detected between high-dose and low-dose glucocorticoid groups (P > 0.05). Multivariate logistic regression analysis revealed that cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis were positively correlated with mortality in patients with multi-organ irAEs (OR > 1, P < 0.05). The most common organ combinations in multi-organ irAEs are “cardiac + neurological, cardiac + pulmonary, thyroid + pituitary, cardiac + hepatic, and gastrointestinal + skin”. Multi-organ irAEs are generally more severe and associated with poorer outcomes compared to single-organ irAEs. High-dose glucocorticoids did not demonstrate superior prognostic outcomes and may be associated with an increased mortality risk in severe irAEs.clinical decisions regarding glucocorticoid dosing should be individualized based on the severity of irAEs and the specific organs involved.Cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis are potential mortality risk factors for multi-organ irAEs induced by ICIs.
- 24 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessClinical characteristics and therapies of multi-organ immune related adverse events
Immune checkpoint inhibitors (ICIs) activate the immune system by blocking PD-1, CTLA-4, and PD-L1, thereby inducing autoimmune-mediated adverse reactions known as immune-related adverse events (irAEs). When two or more organs are involved, this condition is defined as multi-organ immune-related adverse events (multi-organ irAEs). Patients with multi-organ irAEs account for approximately 20%–30% of all irAE cases; however, clinical research focusing on this subset remains limited. The purpose of this study is to analyze the clinical characteristics, optimal therapeutic approaches, and mortality-related risk factors of multi-organ irAEs. We searched all case reports of irAEs associated with ICIs in the PubMed, Web of Science, Cochrane Library, and Embase databases from their inception to January 2022. Search terms included “Immune Checkpoint Inhibitors”, “Checkpoint Inhibitors, Immune”, “Immune Checkpoint Blockers”, “PD-L1”, “CTLA-4 Inhibitor”, “PD-1”, and “Case report”. After removing duplicate literature and applying strict inclusion/exclusion criteria, a total of 2,740 articles were included, encompassing 2,964 patients (782 with multi-organ irAEs and 2,182 with single-organ irAEs). Patients were stratified by the number of affected organs to compare clinical characteristics between multi-organ and single-organ irAE groups. For patients with multi-organ irAEs, subgroup analyzes were performed based on glucocorticoid dosage to identify optimal treatment strategies, and further stratified by survival status to explore potential mortality risk factors. No statistically significant differences in age or sex were observed between patients with multi-organ irAEs and those with single-organ irAEs (P > 0.05). However, the multi-organ irAE group exhibited significantly higher proportions of cardiovascular toxicity, thyroid toxicity, skin toxicity, and severe adverse reactions (P < 0.05), as well as a significantly elevated mortality rate (P < 0.05). Among patients with severe multi-organ irAEs, there were no significant differences in sex or age between high-dose and low-dose glucocorticoid subgroups (P > 0.05); notably, the high-dose glucocorticoid group had a significantly higher mortality rate (P < 0.05). For patients with non-severe multi-organ irAEs, no statistically significant differences in sex, age, mortality, or prognosis were detected between high-dose and low-dose glucocorticoid groups (P > 0.05). Multivariate logistic regression analysis revealed that cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis were positively correlated with mortality in patients with multi-organ irAEs (OR > 1, P < 0.05). The most common organ combinations in multi-organ irAEs are “cardiac + neurological, cardiac + pulmonary, thyroid + pituitary, cardiac + hepatic, and gastrointestinal + skin”. Multi-organ irAEs are generally more severe and associated with poorer outcomes compared to single-organ irAEs. High-dose glucocorticoids did not demonstrate superior prognostic outcomes and may be associated with an increased mortality risk in severe irAEs.clinical decisions regarding glucocorticoid dosing should be individualized based on the severity of irAEs and the specific organs involved.Cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis are potential mortality risk factors for multi-organ irAEs induced by ICIs.
- 3 September 2025
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 52 (10) , e70071
Early and Stable Mouse Model of Amphotericin B‐Induced Acute Kidney Injury: Application of Continuous Non‐Invasive GFR Monitoring
Background: Amphotericin B (AmB) remains a cornerstone in antifungal therapy, but its clinical use is limited by dose‐dependent nephrotoxicity. Lipid‐based formulations such as amphotericin B cholesterol sulfate complex dispersion (ABCD) were developed to mitigate renal injury, though their comparative renal safety profiles remain incompletely defined.Objective: This study aimed to establish a pharmacologically relevant mouse model to characterise the nephrotoxicity of conventional AmB (AmB‐D) and ABCD formulations, using continuous non‐invasive glomerular filtration rate (GFR) monitoring and renal injury biomarkers.Methods: Male C57BL/6 mice received a single intravenous dose of AmB‐D or ABCD at low or high doses. Renal function was assessed via real‐time GFR monitoring, serum creatinine (SCr), blood urea nitrogen (BUN) and mRNA expression of kidney injury molecule‐1 (KIM‐1) and neutrophil gelatinase‐associated lipocalin (NGAL). Histopathological injury was evaluated at defined time points.Results: High‐dose AmB‐D (2 mg/kg) and ABCD (20 mg/kg) induced rapid GFR decline within 2 h, preceding significant increases in SCr, BUN, and injury biomarkers. ABCD demonstrated 6–10‐fold lower nephrotoxic potency compared to AmB‐D. Low‐dose groups exhibited mild, reversible changes in GFR and minimal tubular injury.Conclusion: Continuous GFR monitoring enables sensitive detection of early renal dysfunction and reveals distinct nephrotoxic profiles between AmB‐D and ABCD. This pharmacologically relevant model provides a powerful tool for preclinical nephrotoxicity assessment and for quantitatively comparing the renal safety of different drug formulations.
- 3 September 2025
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 52 (10) , e70071
Early and Stable Mouse Model of Amphotericin B‐Induced Acute Kidney Injury: Application of Continuous Non‐Invasive GFR Monitoring
Background: Amphotericin B (AmB) remains a cornerstone in antifungal therapy, but its clinical use is limited by dose‐dependent nephrotoxicity. Lipid‐based formulations such as amphotericin B cholesterol sulfate complex dispersion (ABCD) were developed to mitigate renal injury, though their comparative renal safety profiles remain incompletely defined.Objective: This study aimed to establish a pharmacologically relevant mouse model to characterise the nephrotoxicity of conventional AmB (AmB‐D) and ABCD formulations, using continuous non‐invasive glomerular filtration rate (GFR) monitoring and renal injury biomarkers.Methods: Male C57BL/6 mice received a single intravenous dose of AmB‐D or ABCD at low or high doses. Renal function was assessed via real‐time GFR monitoring, serum creatinine (SCr), blood urea nitrogen (BUN) and mRNA expression of kidney injury molecule‐1 (KIM‐1) and neutrophil gelatinase‐associated lipocalin (NGAL). Histopathological injury was evaluated at defined time points.Results: High‐dose AmB‐D (2 mg/kg) and ABCD (20 mg/kg) induced rapid GFR decline within 2 h, preceding significant increases in SCr, BUN, and injury biomarkers. ABCD demonstrated 6–10‐fold lower nephrotoxic potency compared to AmB‐D. Low‐dose groups exhibited mild, reversible changes in GFR and minimal tubular injury.Conclusion: Continuous GFR monitoring enables sensitive detection of early renal dysfunction and reveals distinct nephrotoxic profiles between AmB‐D and ABCD. This pharmacologically relevant model provides a powerful tool for preclinical nephrotoxicity assessment and for quantitatively comparing the renal safety of different drug formulations.
- Open Access
- 26 August 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 125-17
Urinary 3-methylhistidine as a potential biomarker for sepsis-associated acute kidney injury: multidimensional metabolomics analysis in mice and human
- 26 August 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 125-17
Open AccessUrinary 3-methylhistidine as a potential biomarker for sepsis-associated acute kidney injury: multidimensional metabolomics analysis in mice and human
- 10 April 2025
- Published by Wiley in Immunology
SAA1 as a Potential Early Diagnostic Biomarker for Sepsis Through Integrated Proteomics and Metabolomics
Sepsis is characterised by fatal organ dysfunction resulting from a dysfunctional host response to infection, imposing a substantial economic burden on families and society. Therefore, identifying biomarkers for early sepsis diagnosis and improving patient prognosis are critical. This study recruited 59 sepsis patients and 35 healthy volunteers from the Department of Critical Care Medicine at Harbin Medical University Affiliated First Hospital between March and December 2021. Through a combination of non‐targeted and targeted proteomics and metabolomics sequencing, along with various analytical methods, we initially identified and validated serum amyloid A1 (SAA1) as a diagnostic biomarker for sepsis. Our study found that SAA1 was significantly elevated in the sepsis group, demonstrating its diagnostic value for sepsis (AUC: 0.95, 95% CI: 0.88–1). Additionally, a positive correlation was observed between SAA1 and disease severity, as indicated by the Sequential Organ Failure Assessment (SOFA) score (R = 0.51, p = 0.004) and Acute Physiology and Chronic Health Evaluation II (APACHE II) score (R = 0.52, p = 0.003). This study suggests that SAA1 is a potentially effective and reliable marker for diagnosing sepsis and predicting its severity.
- 10 April 2025
- Published by Wiley in Immunology
SAA1 as a Potential Early Diagnostic Biomarker for Sepsis Through Integrated Proteomics and Metabolomics
Sepsis is characterised by fatal organ dysfunction resulting from a dysfunctional host response to infection, imposing a substantial economic burden on families and society. Therefore, identifying biomarkers for early sepsis diagnosis and improving patient prognosis are critical. This study recruited 59 sepsis patients and 35 healthy volunteers from the Department of Critical Care Medicine at Harbin Medical University Affiliated First Hospital between March and December 2021. Through a combination of non‐targeted and targeted proteomics and metabolomics sequencing, along with various analytical methods, we initially identified and validated serum amyloid A1 (SAA1) as a diagnostic biomarker for sepsis. Our study found that SAA1 was significantly elevated in the sepsis group, demonstrating its diagnostic value for sepsis (AUC: 0.95, 95% CI: 0.88–1). Additionally, a positive correlation was observed between SAA1 and disease severity, as indicated by the Sequential Organ Failure Assessment (SOFA) score (R = 0.51, p = 0.004) and Acute Physiology and Chronic Health Evaluation II (APACHE II) score (R = 0.52, p = 0.003). This study suggests that SAA1 is a potentially effective and reliable marker for diagnosing sepsis and predicting its severity.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5545-5553
Urine Neutrophil Elastase: A Novel Predictor of ICU Admission for Patients with COVID-19 Infection
Introduction: We aimed to explore the differences of neutrophil elastase (NE) levels between intensive care unit (ICU) and non-ICU patients with COVID-19 infection, as well as its predictive value for COVID-19 progression. Methods: We enrolled the patients admitted with a primary diagnosis of COVID-19. All patients in ICU were diagnosed with the critical type upon admission. Blood was taken within 24 hours, followed by examination of the blood NE level and urine NE level. Other clinical features were recorded. A logistic regression model was used to predict ICU admission. Results: A total of 83 patients were diagnosed, including 52 non-ICU cases and 31 ICU cases. The ICU group showed significantly elevated levels of Neutrophil%, Cr, D-dimer (DD), Procalcitonin (PCT), and C-reactive protein (CRP). Meanwhile, the CD3-cell, T4-cell, and Lymphocyte% levels were lower in the ICU group. Notably, the blood NE levels were similar between groups, whereas the urine NE level was highly significantly higher in the ICU group vs the non-ICU group. After dimension reduction, we constructed a logistic model (UD) using only two factors: the urine NE level and the blood DD level. The overall accuracy of was 86.1%. The urine NE has a strong efficacy in ICU prediction (AUC = 0.893), and the performance of the UD model was even better (AUC = 0.933). Conclusion: Urine NE level is a useful predictor of COVID-19 progression, particularly in patients requiring ICU care. Urine NE has a significantly positive correlation with neutrophil%, DD, and PCT, as well as a negative correlation with lymphocyte levels.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5545-5553
Open AccessUrine Neutrophil Elastase: A Novel Predictor of ICU Admission for Patients with COVID-19 Infection
Introduction: We aimed to explore the differences of neutrophil elastase (NE) levels between intensive care unit (ICU) and non-ICU patients with COVID-19 infection, as well as its predictive value for COVID-19 progression. Methods: We enrolled the patients admitted with a primary diagnosis of COVID-19. All patients in ICU were diagnosed with the critical type upon admission. Blood was taken within 24 hours, followed by examination of the blood NE level and urine NE level. Other clinical features were recorded. A logistic regression model was used to predict ICU admission. Results: A total of 83 patients were diagnosed, including 52 non-ICU cases and 31 ICU cases. The ICU group showed significantly elevated levels of Neutrophil%, Cr, D-dimer (DD), Procalcitonin (PCT), and C-reactive protein (CRP). Meanwhile, the CD3-cell, T4-cell, and Lymphocyte% levels were lower in the ICU group. Notably, the blood NE levels were similar between groups, whereas the urine NE level was highly significantly higher in the ICU group vs the non-ICU group. After dimension reduction, we constructed a logistic model (UD) using only two factors: the urine NE level and the blood DD level. The overall accuracy of was 86.1%. The urine NE has a strong efficacy in ICU prediction (AUC = 0.893), and the performance of the UD model was even better (AUC = 0.933). Conclusion: Urine NE level is a useful predictor of COVID-19 progression, particularly in patients requiring ICU care. Urine NE has a significantly positive correlation with neutrophil%, DD, and PCT, as well as a negative correlation with lymphocyte levels.
- Open Access
- 1 October 2024
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 12 (1) , 1-10
An early and stable mouse model of polymyxin-induced acute kidney injury
Background: Polymyxins have been revived as a last-line therapeutic option for multi-drug resistant bacteria and continue to account for a significant proportion of global antibiotic usage. However, kidney injury is often a treatment limiting event with kidney failure rates ranging from 5 to 13%. The mechanisms underlying polymyxin-induced nephrotoxicity are currently unclear. Researches of polymyxin-associated acute kidney injury (AKI) models need to be more standardized, which is crucial for obtaining consistent and robust mechanistic results. Methods: In this study, male C57BL/6 mice received different doses of polymyxin B (PB) and polymyxin E (PE, also known as colistin) by different routes once daily (QD), twice daily (BID), and thrice daily (TID) for 3 days. We continuously monitored the glomerular filtration rate (GFR) and the AKI biomarkers, including serum creatinine (Scr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). We also performed histopathological examinations to assess the extent of kidney injury. Results: Mice receiving PB (35 mg/kg/day subcutaneously) once daily exhibited a significant decrease in GFR and a notable increase in KIM-1 two hours after the first dose. Changes in GFR and KIM-1 at 24, 48 and 72 h were consistent and demonstrated the occurrence of kidney injury. Histopathological assessments showed a positive correlation between the severity of kidney injury and the changes in GFR and KIM-1 (Spearman’s rho = 0.3167, P = 0.0264). The other groups of mice injected with PB and PE did not show significant changes in GFR and AKI biomarkers compared to the control group. Conclusion: The group receiving PB (35 mg/kg/day subcutaneously) once daily consistently developed AKI at 2 h after the first dose. Establishing an early and stable AKI model facilitates researches into the mechanisms of early-stage kidney injury. In addition, our results indicated that PE had less toxicity than PB and mice receiving the same dose of PB in the QD group exhibited more severe kidney injury than the BID and TID groups.
- 1 October 2024
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 12 (1) , 1-10
Open AccessAn early and stable mouse model of polymyxin-induced acute kidney injury
Background: Polymyxins have been revived as a last-line therapeutic option for multi-drug resistant bacteria and continue to account for a significant proportion of global antibiotic usage. However, kidney injury is often a treatment limiting event with kidney failure rates ranging from 5 to 13%. The mechanisms underlying polymyxin-induced nephrotoxicity are currently unclear. Researches of polymyxin-associated acute kidney injury (AKI) models need to be more standardized, which is crucial for obtaining consistent and robust mechanistic results. Methods: In this study, male C57BL/6 mice received different doses of polymyxin B (PB) and polymyxin E (PE, also known as colistin) by different routes once daily (QD), twice daily (BID), and thrice daily (TID) for 3 days. We continuously monitored the glomerular filtration rate (GFR) and the AKI biomarkers, including serum creatinine (Scr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). We also performed histopathological examinations to assess the extent of kidney injury. Results: Mice receiving PB (35 mg/kg/day subcutaneously) once daily exhibited a significant decrease in GFR and a notable increase in KIM-1 two hours after the first dose. Changes in GFR and KIM-1 at 24, 48 and 72 h were consistent and demonstrated the occurrence of kidney injury. Histopathological assessments showed a positive correlation between the severity of kidney injury and the changes in GFR and KIM-1 (Spearman’s rho = 0.3167, P = 0.0264). The other groups of mice injected with PB and PE did not show significant changes in GFR and AKI biomarkers compared to the control group. Conclusion: The group receiving PB (35 mg/kg/day subcutaneously) once daily consistently developed AKI at 2 h after the first dose. Establishing an early and stable AKI model facilitates researches into the mechanisms of early-stage kidney injury. In addition, our results indicated that PE had less toxicity than PB and mice receiving the same dose of PB in the QD group exhibited more severe kidney injury than the BID and TID groups.